

# New clinical study enrolling pregnant women on lacosamide

## Call for patient recruitment

A multicenter, open-label, longitudinal, prospective, pharmacokinetic phase 1b study in pregnant women with epilepsy treated with lacosamide: a substudy of the Australian Pregnancy Register of Antiepileptic Drugs for Women in Pregnancy with Epilepsy and Allied Conditions (Study UP0121)<sup>1</sup>

The Raoul Wallenberg Australian Pregnancy Register (APR) in collaboration with UCB Pharma would like to announce the commencement of a study of pregnant women currently on lacosamide. The primary objective of the study is to understand how levels of lacosamide change during pregnancy .

The study will involve collection of blood during pregnancy and after the birth, and additionally collect breast milk samples if possible, to determine the level of lacosamide recovered in breast milk. All other study assessments are part of normal care during pregnancy.

We encourage any person that is currently on lacosamide and who is already pregnant or planning on becoming pregnant to speak with the APR, and their Neurologist about this study.

## For more information about the study, or to speak with the Australian Pregnancy Register:

*Phone: 1800 069 722*

*Email: [apr@mh.org.au](mailto:apr@mh.org.au)*

*Website: [www.apr.org.au](http://www.apr.org.au)*

1. <https://www.anzctr.org.au/ACTRN12622001121752.aspx>



This study has been approved by the Melbourne Health Human Ethics Research Committee. Approval number 2015.211 - HREC/11/MH/282. ANZCTR registration number: ACTRN12622001121752

UCB Australia Pty Ltd. Level 1, 1155 Malvern Rd, Malvern 3144. Ph +61 3 9828 1800  
AU-N-VI-EPOS-2200008. Sep 2022.



For pregnant women with epilepsy and/or pregnant women taking antiepileptic drugs for other conditions  
1800 069 722 | [www.apr.org.au](http://www.apr.org.au) | [apr@mh.org.au](mailto:apr@mh.org.au)